Specialty Pharmacy

If IVIG is commenced within 2 weeks from the onset of Guillain-Barre syndrome it can hasten recovery as much as plasma exchange, study indicates.

Results from a phase 3 trial investigating the programmed cell death protein 1 inhibitor cemiplimab monotherapy compared to chemotherapy showed an overall survival benefit among patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.

Electricity may slow the speed at which breast cancer cells spread through the body, and in some cases may stop them entirely, according to a new study published in Bioelectricity.

Investigators found a statistically significant improvement in both overall survival and progression-free survival for patients who received pembrolizumab with chemotherapy.

Low doses of propylparaben–a chemical preservative found in food, drugs, and cosmetics–can alter pregnancy-related changes in the breast in ways that may lessen the protection against breast cancer normally conveyed by pregnancy hormones.

The IGCS Mentorship and Training Program seeks to provide training and education to regions without formal training programs in gynecologic oncology.

Clinicians have been searching for accurate, reliable, non-invasive diagnostic tools to differentiate early stage, less dangerous, and more treatable stages of the disease from the aggressive, high-grade and likely-to-spread forms.

Nine in 10 patients with multiple sclerosis who received the medication did not have worsening of 3-month disability, and ponesimod showed a numerical benefit in delaying disability progression.

Language barriers can present a major obstacle to patient involvement in cancer care, although clinicians recommended several potential strategies to help patients who speak different languages.

Study finds cancer survivors were 42% more likely to report walking at the slowest pace and had a 24% greater risk of mobility disability compared to individuals who never had cancer.

When applied as a filler for soft tissue defects and voids, the regenerative tissue filler shows promise for accelerating and improving tissue restoration outcomes.

The VENTANA ALK CDx assay is a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who are eligible to receive treatment with lorlatinib.

Researchers find no clear therapeutic benefit of intravenous immunoglobulin for the prevention of postnatal relapses of multiple sclerosis.

Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.

Researchers at Columbia and MIT have created a new technique that can uncover nearly all of the behaviors that cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments.

In a recent interview with Pharmacy Times, Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, said the development of chimeric antigen receptor (CAR) T-cell therapies is a major step for the treatment of some cancers.

Women who attended the 2 more recent screenings prior to their breast cancer diagnosis had a 50% lower incidence of their cancer being fatal within 10 years.

Study findings demonstrate the importance of interventions for multiple sclerosis therapy, such as those supporting medication adherence, adverse effect management, symptom management, and additional counseling.

The FDA has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

New protein-based immunotherapies could stimulate patients’ immune systems without needing to engineer T cells on an individual basis.

Investigators are set to begin testing sulfasalazine and auronofin, which are FDA-approved to treat rheumatoid arthritis, in cancer cell models.

The FDA has approved a supplemental new drug application for lorlatinib (Lorbrena) to expand the indication to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

The availability of both intravenous and subcutaneous routes of immunoglobulin has made personalization of treatment more important than ever.

Among the health care professionals staking their ground on social media are a growing list of pharmacists and pharmacy students.

Although there have been many challenges and concerns during the pandemic, experts said there are also lessons to be learned and implemented once the pandemic is over.

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets (Tibsovo) as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

The FDA has approved melphalan flufenamide (Pepaxto; melflufen) for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.

As immunotherapies continue to show promise in more effectively combating several tumor types, many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumors.

Pharmacy Times® interviewed David Silverstein, JD, MS, a partner in Axinn’s Intellectual Property and FDA practice groups, on what may be coming to market in the rapidly growing cell therapy space, and the role pharmacists may play in this emerging landscape.

The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma.